lung cancer

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J buys novel lung cancer drug from South Korea's Yuhan

Janssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer (NSCLC).

News

FDA green lights Pfizer's Lorbrena for aggressive lung cance...

Pfizer’s drug Lorbrena (lorlatinib) can be used to treat certain types of advanced lung cancer.

Views & Analysis

The Frauenkirche is a church in the Bavarian city of Munich that serves as the cathedral of the Archdiocese of Munich and Freising and seat of its Archbishop.

ESMO round-up: Big win for AstraZeneca in ovarian cancer, an...

Several drugmakers announced significant trial findings at this week’s European Society for Medical Oncology (ESMO) conference in Munich.

News

Roche's Tecentriq posts trial wins in two key indications

Roche has scored two big wins with its Tecentriq cancer immunotherapy at ESMO in tough to treat triple negative breast cancer, and untreated lung cancer, as the company plays catch-up with

News

BMS Opdivo fails in small cell lung cancer

Bristol-Myers Squibb has said its Opdivo immunotherapy has failed to improve on standard of care in patients with small cell lung cancer, who had relapsed following platinum-based chemother

News

US regulator backs Pfizer's Vizimpro lung cancer drug

The US drug regulator has given Pfizer’s Vizimpro the green light in a group of lung cancer patients whose tumours have a certain mutation.

J&J buys novel lung cancer drug from South Korea's Yuhan

FDA green lights Pfizer's Lorbrena for aggressive lung cance...

ESMO round-up: Big win for AstraZeneca in ovarian cancer, an...

Roche's Tecentriq posts trial wins in two key indications

BMS Opdivo fails in small cell lung cancer

US regulator backs Pfizer's Vizimpro lung cancer drug

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

lung cancer

Editor's Picks